710 related articles for article (PubMed ID: 18520345)
21. [The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].
Rubio Caballero M; Nogués Biau A; Falguera Sacrest M; Puig Ganau T; Lecha N; Rubio Rivas C
An Med Interna; 2000 Oct; 17(10):533-7. PubMed ID: 11109648
[TBL] [Abstract][Full Text] [Related]
22. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
[TBL] [Abstract][Full Text] [Related]
23. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count.
de Souza VA; Pierrotti LC; Sumita LM; Freire WS; Segurado AA; Pannuti CS
J Med Virol; 2007 Oct; 79(10):1562-8. PubMed ID: 17705173
[TBL] [Abstract][Full Text] [Related]
24. Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
Moore DM; Hogg RS; Braitstein P; Wood E; Yip B; Montaner JS
Antivir Ther; 2006; 11(1):125-9. PubMed ID: 16518968
[TBL] [Abstract][Full Text] [Related]
25. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL.
Kaplan JE; Hanson DL; Cohn DL; Karon J; Buskin S; Thompson M; Fleming P; Dworkin MS;
Clin Infect Dis; 2003 Oct; 37(7):951-8. PubMed ID: 13130408
[TBL] [Abstract][Full Text] [Related]
26. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
27. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
29. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
[TBL] [Abstract][Full Text] [Related]
30. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
31. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
[TBL] [Abstract][Full Text] [Related]
32. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
33. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
34. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy.
Cattelan AM; Calabrò ML; De Rossi A; Aversa SM; Barbierato M; Trevenzoli M; Gasperini P; Zanchetta M; Cadrobbi P; Monfardini S; Chieco-Bianchi L
Int J Oncol; 2005 Sep; 27(3):779-85. PubMed ID: 16077928
[TBL] [Abstract][Full Text] [Related]
35. Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome.
Tedeschi R; Bortolin MT; Bidoli E; Zanussi S; Pratesi C; Vaccher E; Tirelli U; De Paoli P
J Clin Virol; 2012 Apr; 53(4):297-301. PubMed ID: 22244256
[TBL] [Abstract][Full Text] [Related]
36. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.
Tarwater PM; Gallant JE; Mellors JW; Gore ME; Phair JP; Detels R; Margolick JB; Muñoz A
AIDS; 2004 Dec; 18(18):2419-23. PubMed ID: 15622318
[TBL] [Abstract][Full Text] [Related]
38. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
[TBL] [Abstract][Full Text] [Related]
39. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy.
Paton NI; Sangeetha S; Earnest A; Bellamy R
HIV Med; 2006 Jul; 7(5):323-30. PubMed ID: 16945078
[TBL] [Abstract][Full Text] [Related]
40. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.
Bower M; Weir J; Francis N; Newsom-Davis T; Powles S; Crook T; Boffito M; Gazzard B; Nelson M
AIDS; 2009 Aug; 23(13):1701-6. PubMed ID: 19550283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
